Hypervaskularer

Hypervaskularer refers to a pathological condition characterized by an excessive or abnormal proliferation of blood vessels within a tissue or organ. The term is primarily used in German-speaking medical literature, where it describes tumors, cysts, or lesions that exhibit a markedly increased vascular supply compared to normal tissue. In many cases, a hypervaskularer lesion corresponds to a hemangioma, vascular malformation, or a tumor with high angiogenic activity, such as a malignant melanoma or liver metastasis showing rich capillary networks.

Clinicians diagnose hypervaskularer lesions through imaging studies that highlight vascularity. Doppler ultrasound, contrast-enhanced computed tomography, magnetic resonance imaging with dynamic contrast, and angiography are the most common modalities for identifying the extent and pattern of blood vessel growth. In situations where a biopsy is needed, precautions are taken to minimize bleeding, and percutaneous approaches may be guided by imaging to avoid major vessels.

The clinical impact of a hypervaskularer lesion depends on its size, location, and biological behavior. Small, asymptomatic hemangiomas can often be observed with routine follow-up, while larger or symptomatic lesions may require intervention. Treatment options include sclerotherapy, laser therapy, surgical resection, or embolization to reduce vascular supply. In malignant hypervaskularer tumors, systemic chemotherapy and targeted therapies that inhibit angiogenic pathways, such as VEGF inhibitors, are commonly employed. In some cases, high-dose radiation therapy can result in secondary thrombosis and vessel collapse.

Epidemiological data on hypervaskularer lesions are limited, as the terminology is not standardized internationally. However, studies of vascular tumors and malformations indicate that hypervascular lesions affect a broad range of age groups, often presenting in infancy or early childhood for congenital malformations, while acquired hypervascular tumors are more frequent in adults.

Research continues to refine the understanding of the molecular mechanisms driving hypervascularization. The identification of key genetic mutations and signaling pathways—particularly the VEGF and TIE2 pathways—in hypervaskularer lesions has led to the development of novel, more selective antiangiogenic agents. Ongoing clinical trials are assessing the efficacy of these agents in reducing lesion size and preventing complications in patients with hypervaskularer tumors or malformations.